The Medicines Company is a global biopharmaceutical company. The Company is focused on the development of inclisiran, a twice-yearly therapy that allows administration during patients routine visits to their healthcare professionals and potentially contributes to improved patient adherence and sustained lower LDL-C levels. The Company is a subsidiary of Novartis AG.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+0.14%	-0.05%

20-01-06	The Medicines Company Announces Board Changes	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care	CI

Capitalization	6.79B 5.72B 5.22B 4.98B 9.25B 615B 9.61B 60.7B 24.1B 297B 25.47B 24.94B 1,038B	P/E ratio 2017	-2.79x	P/E ratio 2018	-11.4x
Enterprise value	7.34B 6.19B 5.64B 5.39B 10B 665B 10.39B 65.64B 26.06B 321B 27.54B 26.97B 1,122B	EV / Sales 2017	55.1x	EV / Sales 2018	319x
Free-Float	92.97%	Yield 2017 *	-	Yield 2018	-

20-01-06	The Medicines Company Announces Board Changes	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600 Health Care	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P TMI Index	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 1000	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P Global BMI Index	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P Composite 1500	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P 600	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from S&P Biotechnology Select Industry Index	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from NASDAQ Biotechnology Index	CI
20-01-06	The Medicines Company(NasdaqGS:MDCO) dropped from NASDAQ Composite Index	CI
20-01-02	Novartis AG completed the acquisition of The Medicines Company.	CI
19-11-25	World share markets rally on revived trade hopes; dollar gains	RE
19-11-25	World share markets rally on revived trade hopes; dollar gains	RE

24-04-19	Metsera Launches to Lead the Next Generation of Medicines for Obesity and Metabolic Diseases	AQ
20-01-07	The Medicines Company : Announces Effective Date of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022	AQ
20-01-06	The Medicines Company : Announces Effective Date Of Make-Whole Fundamental Change Relating To Its 2.50% Convertible Senior Notes Due 2022, 2.75% Convertible Senior Notes due 2023 and 3.50% Convertible Senior Notes due 2024	BU
20-01-06	MEDICINES CO /DE : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
20-01-06	MEDICINES CO /DE : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

The Medicines Company Stock

Equities

MDCO

US5846881051

Pharmaceuticals

Valuation: The Medicines Company

Latest news: The Medicines Company

Press Releases: The Medicines Company

News in other languages: The Medicines Company

Managers and Directors: The Medicines Company

Generic Pharmaceuticals

Financials

Company Profile

20-01-06	Medicines : Novartis bringt Übernahme von US-Biotech-Firma in trockene Tücher
19-12-30	Les fusions-acquisitions soutenues par la vigueur du marché américain en 2019
19-12-05	EN DIRECT DES MARCHES : Kering / Moncler, FDJ, Engie, Capgemini, Cybergun, Amazon, Fiat Chrysler...
19-11-26	Des marchés dopés à l'optimisme
19-11-25	Point marchés-Les actions profitent des espoirs sur le commerce et des M&A

Manager	Title	Age	Since
Krishna Gorti IRC	Investor Relations Contact	-	-
Stephen M. Rodin LAW	General Counsel	49	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
THE MEDICINES COMPANY	-.--%	+0.14%	-	-	6.79B
SUN PHARMACEUTICAL INDUSTRIES LTD.	-1.01%	+0.14%	-2.80%	+67.20%	44.97B
OTSUKA HOLDINGS CO., LTD.	+7.23%	+13.28%	+30.34%	+158.17%	36.57B
CIPLA LIMITED	+0.11%	+0.11%	-9.55%	+30.29%	11.88B
ZYDUS LIFESCIENCES LIMITED	-1.76%	+1.86%	-4.05%	+91.90%	10.05B
SAM CHUN DANG PHARM. CO., LTD	+2.69%	+7.00%	+196.89%	+928.85%	8.62B
KRKA, D. D.	-0.84%	+1.73%	+43.73%	+121.70%	8.5B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-1.21%	+7.31%	+71.26%	+33.63%	8.19B
ONO PHARMACEUTICAL CO., LTD.	+1.26%	+2.09%	+62.23%	-10.40%	7.8B
GEDEON RICHTER	-0.51%	+1.92%	+9.24%	+47.26%	6.68B
Average	+0.60%	+2.27%	+44.15%	+163.18%	15B
Weighted average by Cap.	+1.43%	+3.78%	+28.13%	+137.13%

	2017	2018
Net sales	44.79M 37.74M 34.42M 32.86M 61M 4.06B 63.38M 400M 159M 1.96B 168M 165M 6.85B	6.14M 5.17M 4.72M 4.5M 8.36M 556M 8.69M 54.87M 21.78M 268M 23.02M 22.55M 938M
Net income	-708M -597M -544M -520M -965M -64.16B -1B -6.33B -2.51B -30.98B -2.66B -2.6B -108B	-123M -104M -94.65M -90.36M -168M -11.15B -174M -1.1B -437M -5.39B -462M -452M -18.83B
Net Debt	498M 419M 383M 365M 678M 45.09B 704M 4.45B 1.77B 21.77B 1.87B 1.83B 76.1B	552M 465M 424M 405M 752M 49.98B 781M 4.93B 1.96B 24.14B 2.07B 2.03B 84.36B